Literature DB >> 18524771

Assembly with the Cul4A-DDB1DCAF1 ubiquitin ligase protects HIV-1 Vpr from proteasomal degradation.

Erwann Le Rouzic1, Marina Morel, Diana Ayinde, Nadia Belaïdouni, Justine Letienne, Catherine Transy, Florence Margottin-Goguet.   

Abstract

Many viruses subvert the host ubiquitin-proteasome system to optimize their life cycle. We recently documented such a mechanism for the human immunodeficiency virus type 1 Vpr protein, which promotes cell cycle arrest by recruiting the DCAF1 adaptor of the Cul4A-DDB1 ubiquitin ligase, a finding now confirmed by several groups. Here we examined the impact of Cul4A-DDB1(DCAF1) on Vpr stability. We show that the Vpr(Q65R) mutant, which is defective in DCAF1 binding, undergoes proteasome-mediated degradation at a higher rate than wild-type Vpr. DCAF1 overexpression stabilizes wild-type Vpr and leads to its cytoplasmic accumulation, whereas it has no effect on the Vpr(Q65R) mutant. Conversely, small interfering RNA-mediated silencing of DCAF1 decreases the steady state amount of the viral protein. Stabilization by DCAF1, which is conserved by Vpr species from human immunodeficiency virus type 2 and the SIVmac strain, results in increased G(2) arrest and requires the presence of DDB1, indicating that it occurs through assembly of Vpr with a functional Cul4A-DDB1(DCAF1) complex. Furthermore, in human immunodeficiency virus type 1-infected cells, the Vpr protein, issued from the incoming viral particle, is destabilized under DCAF1 or DDB1 silencing. Together with our previous findings, our data suggest that Cul4A-DDB1(DCAF1) acts at a dual level by providing Vpr with the equipment for the degradation of specific host proteins and by counter-acting its proteasome targeting by another cellular E3 ubiquitin ligase. This protection mechanism may represent an efficient way to optimize the activity of Vpr molecules that are delivered by the incoming virus before neosynthesis takes place. Targeting the Vpr-DCAF1 interaction might therefore present therapeutic interest.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18524771     DOI: 10.1074/jbc.M710298200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  28 in total

1.  HIV-1 Vpr loads uracil DNA glycosylase-2 onto DCAF1, a substrate recognition subunit of a cullin 4A-ring E3 ubiquitin ligase for proteasome-dependent degradation.

Authors:  Jinwoo Ahn; Thomas Vu; Zach Novince; Jennifer Guerrero-Santoro; Vesna Rapic-Otrin; Angela M Gronenborn
Journal:  J Biol Chem       Date:  2010-09-24       Impact factor: 5.157

2.  Vipirinin, a coumarin-based HIV-1 Vpr inhibitor, interacts with a hydrophobic region of VPR.

Authors:  Eugene Boon Beng Ong; Nobumoto Watanabe; Akiko Saito; Yushi Futamura; Khaled Hussein Abd El Galil; Atsushi Koito; Nazalan Najimudin; Hiroyuki Osada
Journal:  J Biol Chem       Date:  2011-02-28       Impact factor: 5.157

3.  HIV-1 Vpr protein inhibits telomerase activity via the EDD-DDB1-VPRBP E3 ligase complex.

Authors:  Xin Wang; Shailbala Singh; Hae-Yun Jung; Guojun Yang; Sohee Jun; K Jagannadha Sastry; Jae-Il Park
Journal:  J Biol Chem       Date:  2013-04-23       Impact factor: 5.157

4.  Molecular insight into how HIV-1 Vpr protein impairs cell growth through two genetically distinct pathways.

Authors:  Claire Maudet; Matthieu Bertrand; Erwann Le Rouzic; Hichem Lahouassa; Diana Ayinde; Sébastien Nisole; Caroline Goujon; Andrea Cimarelli; Florence Margottin-Goguet; Catherine Transy
Journal:  J Biol Chem       Date:  2011-05-12       Impact factor: 5.157

Review 5.  Delineating HIV-associated neurocognitive disorders using transgenic models: the neuropathogenic actions of Vpr.

Authors:  Christopher Power; Elizabeth Hui; Pornpun Vivithanaporn; Shaona Acharjee; Maria Polyak
Journal:  J Neuroimmune Pharmacol       Date:  2011-09-15       Impact factor: 4.147

Review 6.  Limelight on two HIV/SIV accessory proteins in macrophage infection: is Vpx overshadowing Vpr?

Authors:  Diana Ayinde; Claire Maudet; Catherine Transy; Florence Margottin-Goguet
Journal:  Retrovirology       Date:  2010-04-09       Impact factor: 4.602

7.  Human immunodeficiency virus type 1 Vpr modulates cellular expression of UNG2 via a negative transcriptional effect.

Authors:  Christelle Langevin; Priscilla Maidou-Peindara; Per Arne Aas; Guillaume Jacquot; Marit Otterlei; Geir Slupphaug; Serge Benichou
Journal:  J Virol       Date:  2009-07-22       Impact factor: 5.103

8.  Genomic analysis reveals MATH gene(s) as candidate(s) for Plum pox virus (PPV) resistance in apricot (Prunus armeniaca L.).

Authors:  Elena Zuriaga; José Miguel Soriano; Tetyana Zhebentyayeva; Carlos Romero; Chris Dardick; Joaquín Cañizares; Maria Luisa Badenes
Journal:  Mol Plant Pathol       Date:  2013-05-14       Impact factor: 5.663

9.  Quantitative Proteomic Approach Identifies Vpr Binding Protein as Novel Host Factor Supporting Influenza A Virus Infections in Human Cells.

Authors:  Anne Sadewasser; Katharina Paki; Katrin Eichelbaum; Boris Bogdanow; Sandra Saenger; Matthias Budt; Markus Lesch; Klaus-Peter Hinz; Andreas Herrmann; Thomas F Meyer; Alexander Karlas; Matthias Selbach; Thorsten Wolff
Journal:  Mol Cell Proteomics       Date:  2017-03-13       Impact factor: 5.911

10.  The human immunodeficiency virus type 1 Vpr protein and its carboxy-terminally truncated form induce apoptosis in tumor cells.

Authors:  Mizuho Nonaka; Yoshie Hashimoto; Shin-Nosuke Takeshima; Yoko Aida
Journal:  Cancer Cell Int       Date:  2009-08-12       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.